Subject Index

Acute renal failure (ARF)
  cell necrosis mechanisms  117
  intensive care unit
    patient characteristics  161, 162
    prognosis  169, 170
  treatment
    obstructive renal failure  165
    overview  163–165
    tumor lysis syndrome  165–169, 171
  tumor lysis syndrome, see Tumor lysis syndrome
  uric acid toxicity  117, 118, 139, 140, 150
Alcohol, hyperuricemia risks  16
Alkalization therapy
  acute renal failure related hyperuricemia  164
  tumor lysis syndrome management  71, 82, 99, 168, 169
  uric acid stone management  144
Allopurinol
  drug interactions  38, 39
  hyperuricemia management  16, 17, 29–31, 119, 120
  kidney transplant patient treatment  128, 129
  mechanism of action  36, 166
  pharmacokinetics  37, 38
  tumor lysis syndrome prevention and management  51, 71, 72, 77, 82, 153, 166, 167
  uric acid nephropathy treatment  140, 141, 153
  uric acid stone management  142, 144
Aspirin, hyperuricemia risks  16
Atrial natriuretic peptide, acute renal failure related hyperuricemia management  165
Bone marrow transplantation (BMT)
  cyclosporine A induction of hyperuricemia  108, 109
  hyperuricemia risks and pathophysiology  106–108
  Lesch–Nyhan disease management  110, 111
  metabolic syndrome and hyperuricemia  109, 110
Cancer, see Lymphoma; Tumor lysis syndrome
Cardiovascular disease, hyperuricemia comorbidity  12, 13, 157
  kidney transplant patients  127, 128
Chronic kidney disease, hyperuricemia risks and management  155–158
Colchicine, acute gout management  15
Corticosteroids, acute gout management  15
Cyclosporine A (CsA), hyperuricemia induction  108, 109, 125, 126, 128, 129
Dietary restriction, purines  16
Familial juvenile hyperuricemic nephropathy (FJHN)
  gene mutations  32
  hyperuricemia  31, 32
Fenofibrate, hyperuricemia management  18
Glycogenosis hyperuricemia
clinical characteristics 30
molecular features 31
treatment 31
types 30
Gout
classification 6, 7
clinical features
acute gouty arthritis 10, 11
asymptomatic hyperuricemia 10
chronic tophaceous gout 11, 12
elderly patients 12
intercritical gout 11
overview 2
women 12
young patients 12
diagnosis 10
epidemiology 2, 3
etiology 3–5
management
acute attack 14, 15
hyperuricemia correction 15–18
prophylaxis 15
pathogenesis 5–9

Hemodialysis, tumor lysis syndrome
prevention and management 73, 120, 121
Hyperkalemia
management 152, 153
tumor lysis syndrome pathophysiology
63, 64, 151, 152
Hyperuricemia
acquired causes 8, 16
bone marrow transplantation, see Bone marrow transplantation
cancer, see Lymphoma; Tumor lysis syndrome
classification 6, 7
correction 15–18
definition 2
diagnosis 10
kidney transplantation, see Kidney transplantation
renal, see Renal hyperuricemia
renal toxicity 117, 118, 139, 140, 150
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT)
deficiency, see also Lesch-Nyhan disease
heredity 7
mutations 23–25
function 6, 22, 23
genotype–phenotype correlation 25–28

Insulin resistance, see also Metabolic syndrome
hyperuricemia comorbidity 14
renal hyperuricemia risks 137

Kidney transplantation
chronic rejection 125
hyperuricemia
cardiovascular disease risks 127, 128
chronic allograft nephropathy risks 126, 127
management 128, 129
pathophysiology 125, 126

Lead, gouty nephropathy risks 137, 138
Lesch-Nyhan disease
bone marrow transplantation 110, 111
clinical features 23
epidemiology 22, 23
gene mutations 23–25
genotype-phenotype correlation 25–28
heredity 22
hyperuricemia and consequences 24
treatment 25

Losartan
hyperuricemia management 18, 157
renal urate clearance effects 138

Lymphoma
autologous stem cell transplantation,
peripheral blood progenitor cells 94, 95
high-dose sequential chemotherapy
autologous stem cell transplantation 95–97
Italian experience 100–102
nephrotoxicity prophylaxis 97–99
principles 95
tumor lysis syndrome, see Tumor lysis syndrome

Metabolic syndrome, hyperuricemia risks
following bone marrow transplantation 109, 110
Nephrolithiasis, see Uric acid stones
Nonsteroidal anti-inflammatory drugs (NSAIDs)
  acute gout management 14, 15
gout prophylaxis 15

Phosphoribosyl pyrophosphate (PRPP) metabolism 5
  synthetase
    mutations 7, 29
    overactivity and hyperuricemia clinical characteristics 28
    consequences 29
    molecular features 29
treatment 29, 30
Probenecid
  drug interactions 38, 40
  hyperuricemia management 17
  mechanism of action 39
  pharmacokinetics 40
Purines
  dietary restriction 16
  metabolism 5, 6
Rasburicase
  acute renal failure patients 154, 155
costs 77, 88, 170
drug interactions 38, 42
hyperuricemia management 119, 120
  mechanism of action 41
  pharmacokinetics 41, 42
production 41, 73, 120
  safety 75, 76
tumor lysis syndrome prevention and management
  adults 51, 73–76, 99
  children 83–91
  intensive care unit use 167, 168
Renal hyperuricemia
  clinical characteristics 31, 32
diagnosis 31
familial juvenile hyperuricemic nephropathy 31, 32
molecular features 32
uric acid renal handling
  anion transporter 134, 135, 138, 145
drug interference 134, 135
  hyperuricosuria 138, 139
  hypouricosuria 136, 137
  insulin effects 137
  lead and gouty nephropathy 137, 138
  overview 149, 150
  phases 133, 134
  urate transporter/channel 135, 136
Rhabdomyolysis, acute renal failure related hyperuricemia management 164
Sulfinpyrazone
  acute uric acid nephropathy induction 140
  hyperuricemia management 17
Syndrome X, see Metabolic syndrome
Tumor lysis syndrome (TLS)
  clinical features 80, 81
  history of study 48, 61
  incidence 62
  incidence by disease
    Burkitt’s lymphoma 54, 55
    childhood tumors 81, 82
    multiple myeloma 56
    non-Hodgkin’s lymphoma 55
    risk stratification by pathology 53, 54, 81, 151
  laboratory evaluation 82, 83
  pathophysiology
    acute renal failure 65, 66, 84, 85, 99, 116, 151
    hyperkalemia 63, 64, 151, 152
    hyperphosphatemia 64, 65
    hyperuricemia 65
    hypocalcemia 65
    metabolic acidosis 66, 67
    overview 63, 69
  prevention and management
    alkañinization of body fluids 71, 82, 99, 153, 168, 169
    allopurinol 51, 71, 72, 77, 82, 153, 166, 167
    children 82–91
costs 171
  hemodialysis 73, 120, 121
  hydration and forced diuresis 70, 82, 98, 99, 153, 168
Tumor lysis syndrome (TLS) (continued)
prevention and management (continued)
mineral disturbances 168, 169
rasburicase 51, 73–76, 83–91, 99, 167, 168
prognosis 169, 170
risk factors for morbidity and mortality 48–50, 62, 81
therapeutic agents and risks
monoclonal antibodies 52, 53
nucleoside analogs 52
overview 51, 52, 62, 151

Urate crystals
arthritis induction 4
inflammatory response 5
phagocytosis 4, 5
precipitation factors 4
solubility factors 3, 4
underexcretion of urate 8, 9

Urate oxidase
mutations 2
recombinant form for hyperuricemia
management, see Rasburicase
Uricozyme therapy 73, 120, 153, 164, 167

Uric acid
antioxidant activity 155
blood levels 132, 133
ionization 132
nephrolithiasis, see Uric acid stones
nephrotoxicity 117, 118, 139, 140, 150
renal handling
anion transporter 134, 135, 138, 145
drug interference 134, 135
hyperuricosuria 138, 139
hypouricosuria 136, 137
insulin effects 137
lead and gouty nephropathy 137, 138
overview 149, 150
phases 133, 134
urate transporter/channel 135, 136
turnover rate 133

Uric acid stones
incidence 141
pathophysiology 141–143
treatment 143, 144
Uricozyme, see Urate oxidase

Xanthine oxidase (XO)
function 6
inhibition, see Allopurinol